Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases

In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetic...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology and immunology research 2022-10, Vol.3 (3), p.103-110
Main Authors: de la Calle-Fabregat, Carlos, Rodríguez-Ubreva, Javier, Cañete, Juan D, Ballestar, Esteban
Format: Article
Language:English
Subjects:
Arthritis
Autoimmune diseases
Biomarkers
DNA methylation
Enzymes
Epigenetics
Gene expression
Genomes
Inflammatory diseases
Kinases
Mutation
Review
Rheumatic diseases
RNA polymerase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetics provides potential mechanisms that determine gene function, are linked to environmental factors, and could explain a wide range of phenotypic variability among patients with these diseases. Despite the high interest and number of studies describing epigenetic alterations under these conditions and exploring their relationship to various clinical aspects, few of the proposed biomarkers have yet reached clinical practice. The potential of epigenetic markers is high, as these alterations link measurable features with a number of biological traits. In the present article, we present published studies in the field, discuss some frequent limitations in the existing research, and propose a number of considerations that should be taken into account by those starting new projects in the field, with an aim to generate biomarkers that could make it into the clinics.
ISSN:2719-4523
2719-4523
DOI:10.2478/rir-2022-0018